We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Metabolic Biomarker Panel Shows Promise for Diagnosis of Dementia

By LabMedica International staff writers
Posted on 22 Sep 2021
A biomarker panel based on five groups of metabolites was shown to be potentially useful for diagnosis and therapy of various forms of dementia, such as Alzheimer’s disease.

Dementia, which is caused by factors that damage neurons, is characterized by a slowly progressing, chronic, and usually irreversible decline in cognitive function. More...
The exact cause of neuron damage, and methods for its detection and treatment have remained elusive.

To rectify this situation, investigators at the Okinawa Institute of Science and Technology (Japan) employed nontargeted liquid chromatography–mass spectroscopy (LC-MS) to quantify small molecular markers in whole blood samples taken from of dementia patients. For this study, the investigators exhaustively analyzed blood samples collected from eight patients with dementia, from eight healthy elderly individuals, and from eight healthy young individuals. Overall, the investigators measured the levels of 124 different metabolites for each patient.

Analysis of the results revealed that 33 metabolites, classified into five groups (A to E), differed significantly in dementia patients, compared with healthy elderly subjects. Seven Group A metabolites present in plasma, including quinolinic acid, kynurenine, and indoxyl-sulfate, increased. The investigators suggested that these compounds may act as neurotoxins, damaging the central nervous system.

The remaining 26 compounds (in groups B to E) decreased in dementia patients, possibly causing a loss of support or protection of the brain in dementia. These compounds were thought to protect the nervous system against oxidative stress, maintain energy reserves, supply nutrients and act as neuroprotective factors.

“Identification of these compounds means that we are one step closer to being able to molecularly diagnose dementia,” said senior author Dr. Mitsuhiro Yanagida, head of the G0 Cell Unit at the Okinawa Institute of Science and Technology. “It is still too early to say, but it could suggest a possible mechanistic cause of dementia as these compounds may lead to impairment of the brain. In the future, we hope to start some intervention studies, either by supplementing dementia patients with metabolic compounds in sub-groups B-E, or by inhibiting the neurotoxins from sub-group A, to see if that can slow, prevent, or even reverse symptoms of dementia.”

The dementia study was published in the September 14, 2021, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America.

Related Links:

Okinawa Institute of Science and Technology


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.